Gilead, Galapagos clear another PhII hurdle for filgotinib, but can they hope to catch up with Novartis’ Cosentyx?

Gilead and Galapagos have cleared another hurdle in a broad-ranging program to advance filgotinib into the market as a blockbuster candidate. But this latest achievement still leaves them way behind a surging Novartis in a packed field of rivals.